Adagene's ADG126 Shows Promise in Combination Therapy for Advanced Solid Tumors

Adagene's Innovative Approach to Cancer Treatment

Adagene Inc., a company at the forefront of antibody discovery and development, has announced a significant development in its cancer treatment research. The company will present a poster on its masked anti-CTLA-4 SAFEbody ADG126, also known as muzastotug, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain 1

1

The Promise of ADG126 in Combination Therapy

The poster presentation will focus on the use of ADG126 in combination with anti-PD-1 therapy for patients with advanced solid tumors. This combination approach represents a potentially powerful strategy in the fight against cancer, as it targets two critical immune checkpoints simultaneously 2

2

SAFEbody Technology: A Game-Changer in Cancer Treatment

ADG126 is based on Adagene's proprietary SAFEbody technology. This innovative approach involves a masked antibody designed to be preferentially activated in the tumor microenvironment. By doing so, it aims to minimize on-target off-tumor toxicity, a common challenge in cancer treatments 1

1

Details of the Poster Presentation

The poster, titled "A phase 1b/2 study of ADG126 (anti-CTLA-4 SAFEbody) plus anti-PD-1 in patients with advanced solid tumors," will be presented on October 21, 2023. It will showcase data from an ongoing Phase 1b/2 clinical trial, providing insights into the efficacy and safety profile of this combination therapy 2

2

Related Stories

Adagene's ADG126 Shows Promising Results in Combination with Keytruda at ESMO Congress

Transgene and BioInvent to Present Groundbreaking Oncolytic Virus BT-001 at ESMO 2024

Guardant Health to Present Groundbreaking Precision Oncology Data at ESMO 2024

SOPHiA GENETICS Unveils Groundbreaking AI-Driven Patient Stratification Research at ESMO 2024

Implications for Cancer Treatment

The presentation of this data at ESMO 2023 marks a significant milestone in Adagene's research and development efforts. It underscores the potential of ADG126 to address unmet needs in cancer treatment, particularly for patients with advanced solid tumors who may have limited treatment options 1

1

Looking Ahead

As the medical community eagerly awaits the full presentation of the data, there is growing anticipation about the potential impact of ADG126 on cancer treatment paradigms. The combination of ADG126 with anti-PD-1 therapy could potentially offer a more effective and safer treatment option for patients with advanced solid tumors 2

2